Pfizer gets reprimanded by UK agency for journal ad
Pharma Compliance Alert, March 21, 2007
Pfizer got a slap on the wrist earlier this month when the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) requested that the company withdraw one of its ads because of potentially misleading claims.
The ad in question was for the antibiotic Zyvox and appeared in the British Medical Journal. According to MHRA, the ad claimed that Zyvox had "superior cure rates compared to products containing the active ingredient vancomycin." However, at the time the ad ran, Pfizer was in discussion with MHRA about emerging concerns about the efficacy and safety of Zyvox compared to vancomycin.
Pfizer suspended the ads, and MHRA told the company to continually review ads in light of new information that may emerge about its drugs.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- Case Management Monthly, June 2012
- Searched